×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Artifacts
/
Microglia in Alzheimer's Disease Neurodegeneration
📖
Microglia in Alzheimer's Disease Neurodegeneration
wiki page
Created: 2026-04-02T19:42:30
By: crosslink-v3
Quality:
50%
✓ SciDEX
ID: wiki-cell-types-microglia-alzheimer-dise
Linked Artifacts (1216)
related
🧪
HSP90-Tau Disaggregation Complex Enhancement
80%
related
🧪
VCP-Mediated Autophagy Enhancement
80%
related
🧪
LRP1-Dependent Tau Uptake Disruption
80%
related
🧪
Extracellular Vesicle Biogenesis Modulation
80%
related
🧪
Synaptic Vesicle Tau Capture Inhibition
80%
related
🧪
TREM2-mediated microglial tau clearance enhancement
80%
related
🧪
Trans-Synaptic Adhesion Molecule Modulation
80%
related
🧪
Cell-Type Specific TREM2 Upregulation in DAM Microglia
80%
related
🧪
GFAP-Positive Reactive Astrocyte Subtype Delineation
80%
related
🧪
Complement C1QA Spatial Gradient in Cortical Layers
80%
related
🧪
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
80%
related
🧪
APOE Isoform Expression Across Glial Subtypes
80%
related
🧪
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
80%
related
🧪
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
80%
related
🧪
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
80%
related
🧪
Prefrontal sensory gating circuit restoration via PV interne
80%
related
🧪
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
80%
related
🧪
Gamma entrainment therapy to restore hippocampal-cortical sy
80%
related
🧪
Temporal Decoupling via Circadian Clock Reset
80%
related
🧪
TREM2 Conformational Stabilizers for Synaptic Discrimination
80%
related
🧪
Netrin-1 Gradient Restoration
80%
related
🧪
Smartphone-Detected Motor Variability Correction
80%
related
🧪
Purinergic Signaling Polarization Control
80%
related
🧪
Mitochondrial-Lysosomal Contact Site Engineering
80%
related
🧪
Osmotic Gradient Restoration via Selective AQP1 Enhancement
80%
related
🧪
Circadian-Synchronized Proteostasis Enhancement
80%
related
🧪
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
80%
related
🧪
Selective HDAC3 Inhibition with Cognitive Enhancement
80%
related
🧪
Selective APOE4 Degradation via Proteolysis Targeting Chimer
80%
related
🧪
Ganglioside Rebalancing Therapy
80%
related
🧪
Mitochondrial SPM Synthesis Platform Engineering
80%
related
🧪
CX43 hemichannel engineering enables size-selective mitochon
80%
related
🧪
Arginine Methylation Enhancement Therapy
80%
related
🧪
Senescent Cell Mitochondrial DNA Release
80%
related
🧪
SASP-Mediated Cholinergic Synapse Disruption
80%
related
🧪
Multi-Modal Stress Response Harmonization
80%
related
🧪
Complement C1q Mimetic Decoy Therapy
80%
related
🧪
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
80%
related
🧪
RAB27A-dependent extracellular vesicle engineering for mitoc
80%
related
🧪
CYP46A1 Overexpression Gene Therapy
80%
related
🧪
Enteric Nervous System Prion-Like Propagation Blockade
80%
related
🧪
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
80%
related
🧪
Retinal Vascular Microcirculation Rescue
80%
related
🧪
Metabolic Reprogramming via Microglial Glycolysis Inhibition
80%
related
🧪
Astroglial Gap Junction Coordination via Connexin-43 Phospho
80%
related
🧪
Metabolic Circuit Breaker via Lipid Droplet Modulation
80%
related
🧪
Senescent Microglia Resolution via Maresins-Senolytics Combi
80%
related
🧪
Noradrenergic-Tau Propagation Blockade
80%
related
🧪
Adenosine-Astrocyte Metabolic Reset
80%
related
🧪
AMPK hypersensitivity in astrocytes creates enhanced mitocho
80%
related
🧪
APOE4 Allosteric Rescue via Small Molecule Chaperones
80%
related
🧪
Palmitoylation-Targeted BACE1 Trafficking Disruptors
80%
related
🧪
Microglial Efferocytosis Enhancement via GPR32 Superagonists
80%
related
🧪
Biorhythmic Interference via Controlled Sleep Oscillations
80%
related
🧪
Quantum Coherence Disruption in Cellular Communication
80%
related
🧪
Nutrient-Sensing Epigenetic Circuit Reactivation
80%
related
🧪
Cryptic Exon Silencing Restoration
80%
related
🧪
SIRT6-NAD+ Axis Enhancement Therapy
80%
related
🧪
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
80%
related
🧪
Circadian Rhythm Entrainment of Reactive Astrocytes
80%
related
🧪
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
80%
related
🧪
SASP-Mediated Complement Cascade Amplification
80%
related
🧪
Complement C1q Subtype Switching
80%
related
🧪
Microglial Purinergic Reprogramming
80%
related
🧪
Heat Shock Protein 70 Disaggregase Amplification
80%
related
🧪
Autophagosome Maturation Checkpoint Control
80%
related
🧪
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
80%
related
🧪
Glymphatic System-Enhanced Antibody Clearance Reversal
80%
related
🧪
Chaperone-Mediated APOE4 Refolding Enhancement
80%
related
🧪
Sphingolipid Metabolism Reprogramming
80%
related
🧪
PARP1 Inhibition Therapy
80%
related
🧪
Low Complexity Domain Cross-Linking Inhibition
80%
related
🧪
Ocular Immune Privilege Extension
80%
related
🧪
Hypocretin-Neurogenesis Coupling Therapy
80%
related
🧪
Gut Barrier Permeability-α-Synuclein Axis Modulation
80%
related
🧪
GAP43-mediated tunneling nanotube stabilization enhances neu
80%
related
🧪
Extracellular Matrix Stiffness Modulation
80%
related
🧪
Pericyte Contractility Reset via Selective PDGFR-β Agonism
80%
related
🧪
Microbial Metabolite-Mediated α-Synuclein Disaggregation
80%
related
🧪
Perforant Path Presynaptic Terminal Protection Strategy
80%
related
🧪
Optogenetic Microglial Deactivation via Engineered Inhibitor
80%
related
🧪
DNMT1-Targeting Antisense Oligonucleotide Reset
80%
related
🧪
Senescence-Induced Lipid Peroxidation Spreading
80%
related
🧪
Piezoelectric Nanochannel BBB Disruption
80%
related
🧪
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
80%
related
🧪
Lipid Droplet Dynamics as Phenotype Switches
80%
related
🧪
Circadian-Synchronized LRP1 Pathway Activation
80%
related
🧪
Glycine-Rich Domain Competitive Inhibition
80%
related
🧪
SASP-Driven Aquaporin-4 Dysregulation
80%
related
🧪
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
80%
related
🧪
Circadian-Gated Maresin Biosynthesis Amplification
80%
related
🧪
Synthetic Biology BBB Endothelial Cell Reprogramming
80%
related
🧪
Orexin-Microglia Modulation Therapy
80%
related
🧪
KDM6A-Mediated H3K27me3 Rejuvenation
80%
related
🧪
Lysosomal Membrane Repair Enhancement
80%
related
🧪
Sleep Spindle-Synaptic Plasticity Enhancement
80%
related
🧪
Lysosomal Calcium Channel Modulation Therapy
80%
related
🧪
Astrocyte-Mediated Neuronal Epigenetic Rescue
80%
related
🧪
Blood-Brain Barrier SPM Shuttle System
80%
related
🧪
Mitochondrial Transfer Pathway Enhancement
80%
related
🧪
Stress Granule Phase Separation Modulators
80%
related
🧪
TFAM overexpression creates mitochondrial donor-recipient gr
80%
related
🧪
Interfacial Lipid Mimetics to Disrupt Domain Interaction
80%
related
🧪
Pharmacological Enhancement of APOE4 Glycosylation
80%
related
🧪
Membrane Cholesterol Gradient Modulators
80%
related
🧪
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
80%
related
🧪
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
80%
related
🧪
Flotillin-1 Stabilization Compounds
80%
related
🧪
Metabolic Switch Targeting for A1→A2 Repolarization
80%
related
🧪
Targeted APOE4-to-APOE3 Base Editing Therapy
80%
related
🧪
Temporal TET2-Mediated Hydroxymethylation Cycling
80%
related
🧪
HDAC3-Selective Inhibition for Clock Reset
80%
related
🧪
Magnetosonic-Triggered Transferrin Receptor Clustering
80%
related
🧪
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
80%
related
🧪
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
80%
related
🧪
Chromatin Accessibility Restoration via BRD4 Modulation
80%
related
🧪
Transcriptional Autophagy-Lysosome Coupling
80%
related
🧪
Digital Twin-Guided Metabolic Reprogramming
80%
related
🧪
Lysosomal Positioning Dynamics Modulation
80%
related
🧪
Lysosomal Enzyme Trafficking Correction
80%
related
🧪
Circadian Clock-Autophagy Synchronization
80%
related
🧪
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
80%
related
🧪
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
80%
related
🧪
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
80%
related
🧪
Senescence-Associated Myelin Lipid Remodeling
80%
related
🧪
Glial Glycocalyx Remodeling Therapy
80%
related
🧪
R-Loop Resolution Enhancement Therapy
80%
related
🧪
Aquaporin-4 Polarization Rescue
80%
related
🧪
Senescence-Activated NAD+ Depletion Rescue
80%
related
🧪
Competitive APOE4 Domain Stabilization Peptides
80%
related
🧪
Epigenetic Memory Erasure via TET2 Activation
80%
related
🧪
Reelin-Mediated Cytoskeletal Stabilization Protocol
80%
related
🧪
HCN1-Mediated Resonance Frequency Stabilization Therapy
80%
related
🧪
TET2-Mediated Demethylation Rejuvenation Therapy
80%
related
🧪
Mechanosensitive Ion Channel Reprogramming
80%
related
🧪
Serine/Arginine-Rich Protein Kinase Modulation
80%
related
🧪
Selective Acid Sphingomyelinase Modulation Therapy
80%
related
🧪
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
80%
related
🧪
Vocal Cord Neuroplasticity Stimulation
80%
related
🧪
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
80%
related
🧪
Synthetic Biology Rewiring via Orthogonal Receptors
80%
related
🧪
Ephrin-B2/EphB4 Axis Manipulation
80%
related
🧪
Microbial Inflammasome Priming Prevention
80%
related
🧪
Phase-Separated Organelle Targeting
80%
related
🧪
Nucleolar Stress Response Normalization
80%
related
🧪
Vagal Afferent Microbial Signal Modulation
80%
related
🧪
Cross-Seeding Prevention Strategy
80%
related
🧪
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
80%
related
🧪
Purinergic P2Y12 Inverse Agonist Therapy
80%
related
🧪
Microbiome-Derived Tryptophan Metabolite Neuroprotection
80%
related
🧪
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
80%
related
🧪
Near-infrared light therapy stimulates COX4-dependent mitoch
80%
related
🧪
FOXO3-Longevity Pathway Epigenetic Reprogramming
80%
related
🧪
Sphingomyelin Synthase Activators for Raft Remodeling
80%
see_also
📖
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE
80%
see_also
📖
UPenn Observational Research Repository (NCT04715399)
80%
see_also
📖
Cell-Free DNA Biomarkers in Neurodegeneration
80%
see_also
📖
Exosomal Biomarkers in Neurodegeneration
80%
see_also
📖
Exosomal miR-155 in Neurodegeneration
80%
see_also
📖
IL-6 (Interleukin-6) in Neurodegeneration
80%
see_also
📖
Liquid Biopsy in Neurodegeneration
80%
see_also
📖
Metabolomic Biomarkers in Neurodegeneration
80%
see_also
📖
Neuroimaging Biomarkers for Neurodegeneration
80%
see_also
📖
Synaptic Biomarkers in Neurodegeneration
80%
see_also
📖
BEACoN Study - Biomarker Exploration in Aging, Cognition and
80%
see_also
📖
Olfactory Mucosa, Blood and Urine for Identification of Earl
80%
see_also
📖
Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration
80%
see_also
📖
Beta-Propeller Protein-Associated Neurodegeneration (BPAN)
80%
see_also
📖
China Neurodegeneration Epidemiology
80%
see_also
📖
DALY Methodology — Neurodegeneration
80%
see_also
📖
Disease Progression & Staging in Neurodegeneration
80%
see_also
📖
Economic Burden — Neurodegeneration
80%
see_also
📖
European Neurodegeneration Epidemiology
80%
see_also
📖
Familial vs Sporadic Neurodegeneration Comparison
80%
see_also
📖
Global Neurodegeneration Epidemiology
80%
see_also
📖
India Neurodegeneration Epidemiology
80%
see_also
📖
Japan Neurodegeneration Epidemiology
80%
see_also
📖
Manganese-Related Neurodegeneration (Manganism)
80%
see_also
📖
mitochondrial-dysfunction-neurodegeneration-comparison
80%
see_also
📖
Mitochondrial Diseases and Neurodegeneration Comparison Matr
80%
see_also
📖
Mitochondrial Membrane Protein-Associated Neurodegeneration
80%
see_also
📖
Neurodegeneration with Brain Iron Accumulation (NBIA)
80%
see_also
📖
Potential Impact Measures — Neurodegeneration
80%
see_also
📖
Pantothenate Kinase-Associated Neurodegeneration (PKAN)
80%
see_also
📖
Pantothenate Kinase-Associated Neurodegeneration (PKAN)
80%
see_also
📖
PLA2G6-Associated Neurodegeneration (PLAN)
80%
see_also
📖
Sleep Disorders in Neurodegeneration
80%
see_also
📖
US Neurodegeneration Epidemiology
80%
see_also
📖
acetylcholine-signaling-neurodegeneration
80%
see_also
📖
Advanced Glycation End Products in Neurodegeneration
80%
see_also
📖
Advanced In Vitro Models for Neurodegeneration — Organoids,
80%
see_also
📖
Amylin Signaling in Neurodegeneration
80%
see_also
📖
Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration
80%
see_also
📖
Autosis Pathway in Neurodegeneration
80%
see_also
📖
Basal Ganglia Circuit Dysfunction in Neurodegeneration
80%
see_also
📖
becn1-autophagy-initiation-neurodegeneration-causal-chain
80%
see_also
📖
CaMKII Signaling Pathway in Neurodegeneration
80%
see_also
📖
Carbonic Anhydrase Modulator Therapy in Neurodegeneration
80%
see_also
📖
Cholinergic System Dysfunction in Neurodegeneration
80%
see_also
📖
Chrononutrition and Time-Restricted Eating in Neurodegenerat
80%
see_also
📖
Neural Circuits in Neurodegeneration
80%
see_also
📖
Cognitive Reserve and Resilience in Neurodegeneration
80%
see_also
📖
Computational Disease Models for Neurodegeneration
80%
see_also
📖
Copper Homeostasis in Neurodegeneration
80%
see_also
📖
Diffusion MRI (DTI) in Neurodegeneration
80%
see_also
📖
Digital Phenotyping in Neurodegeneration
80%
see_also
📖
Endocannabinoid System in Neurodegeneration
80%
see_also
📖
Endothelin Signaling Pathway in Neurodegeneration
80%
see_also
📖
epigenetics-neurodegeneration
80%
see_also
📖
ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration
80%
see_also
📖
FA2H-Associated Neurodegeneration Pathway
80%
see_also
📖
Farnesoid X Receptor (FXR) Signaling in Neurodegeneration
80%
see_also
📖
Gangliosides in Neurodegeneration
80%
see_also
📖
GDF15/GDF11 Signaling in Neurodegeneration
80%
see_also
📖
GDNF Signaling Pathway in Neurodegeneration
80%
see_also
📖
Ghrelin Signaling Pathway in Neurodegeneration
80%
see_also
📖
Glucocorticoid Signaling Pathway in Neurodegeneration
80%
see_also
📖
Glycosylation in Neurodegeneration
80%
see_also
📖
Hippocampal Neurogenesis in Neurodegeneration
80%
see_also
📖
Histone Modification Pathways in Neurodegeneration
80%
see_also
📖
Homocysteine Neurotoxicity and Neurodegeneration
80%
see_also
📖
IGF-1 Signaling Pathway in Neurodegeneration
80%
see_also
📖
Integrated Stress Response in Neurodegeneration
80%
see_also
📖
interleukin-6-signaling-neurodegeneration
80%
see_also
📖
Intrinsic Apoptosis Pathway in Neurodegeneration
80%
see_also
📖
Ion Channel Dysfunction in Neurodegeneration: Cross-Disease
80%
see_also
📖
Kidney-Brain Neurodegeneration Axis
80%
see_also
📖
Lipid Dysregulation in Neurodegeneration
80%
see_also
📖
Lysosomal Calcium Dysregulation in Neurodegeneration
80%
see_also
📖
Magnetic Resonance Spectroscopy in Neurodegeneration
80%
see_also
📖
Metal Homeostasis Dysregulation in Neurodegeneration
80%
see_also
📖
Metal Homeostasis in Neurodegeneration
80%
see_also
📖
MicroRNA Dysfunction in Neurodegeneration
80%
see_also
📖
Mineralocorticoid Receptor Signaling in Neurodegeneration
80%
see_also
📖
Mitochondrial Dynamics Pathway in Neurodegeneration
80%
see_also
📖
Mitochondrial Fusion in Neurodegeneration
80%
see_also
📖
Molecular Chaperones in Neurodegeneration
80%
see_also
📖
mTOR Signaling in Neurodegeneration
80%
see_also
📖
mTOR Signaling Pathway in Neurodegeneration
80%
see_also
📖
Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N
80%
see_also
📖
Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati
80%
see_also
📖
Neuronal Hyperexcitability in Neurodegeneration
80%
see_also
📖
Neuropil Threads in Neurodegeneration
80%
see_also
📖
Neurotensin Signaling in Neurodegeneration
80%
see_also
📖
NF-kB Signaling Pathway in Neurodegeneration
80%
see_also
📖
Nitric Oxide Signaling in Neurodegeneration
80%
see_also
📖
Noradrenergic Signaling Pathway in Neurodegeneration
80%
see_also
📖
Neuropeptide Y Signaling in Neurodegeneration
80%
see_also
📖
NRF2 Signaling Pathway in Neurodegeneration
80%
see_also
📖
Nuclear Pore Complex Dysfunction in Neurodegeneration
80%
see_also
📖
Orexin Signaling in Neurodegeneration
80%
see_also
📖
OSK Reprogramming and Yamanaka Factors in Neurodegeneration
80%
see_also
📖
P-Body (Processing Body) Pathway in Neurodegeneration
80%
see_also
📖
Paranodal Dysfunction in Neurodegeneration
80%
see_also
📖
Paraptosis in Neurodegeneration
80%
see_also
📖
Parthanatos in Neurodegeneration
80%
see_also
📖
Pericyte Loss in Neurodegeneration
80%
see_also
📖
PKR Pathway in Neurodegeneration
80%
see_also
📖
Prion Diseases in Neurodegeneration
80%
see_also
📖
Prion-Like Spread in Neurodegeneration
80%
see_also
📖
Prion Protein Metabolism in Neurodegeneration
80%
see_also
📖
Progesterone Signaling Pathway in Neurodegeneration
80%
see_also
📖
Prognostic Biomarkers in Neurodegeneration
80%
see_also
📖
Protein Aggregation Comparison in Neurodegeneration
80%
see_also
📖
Protein Aggregation Seeds in Neurodegeneration
80%
see_also
📖
Protein O-GlcNAcylation Pathway in Neurodegeneration
80%
see_also
📖
Cortical Involvement and Neurodegeneration in Progressive Su
80%
see_also
📖
Purinergic Signaling in Neurodegeneration
80%
see_also
📖
Quantum Biology and Coherent Energy Transfer in Neurodegener
80%
see_also
📖
R-Loop Stress in Neurodegeneration
80%
see_also
📖
RAN Translation in Neurodegeneration
80%
see_also
📖
Ribosome Dysfunction in Neurodegeneration
80%
see_also
📖
RNA Splicing in Neurodegeneration
80%
see_also
📖
Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a
80%
see_also
📖
S100 Protein Signaling Pathway in Neurodegeneration
80%
see_also
📖
Serotonergic Dysfunction in Neurodegeneration
80%
see_also
📖
Short Chain Fatty Acids in Neurodegeneration
80%
see_also
📖
Sigma-1 Receptor Signaling in Neurodegeneration
80%
see_also
📖
Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration
80%
see_also
📖
Sleep Dysfunction in Neurodegeneration
80%
see_also
📖
SUMOylation in Neurodegeneration
80%
see_also
📖
synaptic-vesicle-cycling-neurodegeneration
80%
see_also
📖
Synthetic Lethality and PARP Inhibition in Neurodegeneration
80%
see_also
📖
T-Cell Dysfunction in Neurodegeneration
80%
see_also
📖
Tertiary Lymphoid Organs in Neurodegeneration
80%
see_also
📖
ubiquitin-proteasome-dysfunction-neurodegeneration
80%
see_also
📖
Ubiquitin-Proteasome System Dysfunction in Neurodegeneration
80%
see_also
📖
Vagus Nerve Pathway in Neurodegeneration
80%
see_also
📖
VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio
80%
see_also
📖
vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio
80%
see_also
📖
WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen
80%
see_also
📖
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
80%
see_also
📖
Extracellular Vesicle and Tunneling Nanotube-Mediated Spread
80%
see_also
📖
Antibody Therapy in Neurodegeneration
80%
see_also
📖
Axon Guidance Pathways in Neurodegeneration
80%
see_also
📖
Cerebral Amyloid Angiopathy in Neurodegeneration
80%
see_also
📖
Cerebral Amyloid Angiopathy Pathway in Neurodegeneration
80%
see_also
📖
Convergent Pathways in Neurodegeneration
80%
see_also
📖
COVID-19 Neurodegeneration Mechanism
80%
see_also
📖
Down Syndrome Neurodegeneration Pathway
80%
see_also
📖
Dystrophic Neurites in Neurodegeneration
80%
see_also
📖
Galectin-3 Mechanism in Neurodegeneration
80%
see_also
📖
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration
80%
see_also
📖
HMGB1 Signaling in Neurodegeneration
80%
see_also
📖
IL-1 Signaling Pathway in Neurodegeneration
80%
see_also
📖
Lipid Metabolism Dysregulation in Neurodegeneration
80%
see_also
📖
Microglial Priming Pathway in Neurodegeneration
80%
see_also
📖
Neurovascular Unit Dysfunction in Neurodegeneration
80%
see_also
📖
Peripheral Immune-Brain Crosstalk in Neurodegeneration
80%
see_also
📖
PPAR Signaling Pathway in Neurodegeneration
80%
see_also
📖
Retinal Degeneration Pathway in Neurodegeneration
80%
see_also
📖
RNA-Targeted Therapies in Neurodegeneration
80%
see_also
📖
Sex Differences in Neurodegeneration
80%
see_also
📖
Therapeutic Targets in Neurodegeneration
80%
see_also
📖
Transdiagnostic Proteomic Changes in Neurodegeneration
80%
see_also
📖
Transdiagnostic Proteomic Changes in Neurodegeneration
80%
see_also
📖
Endosomal-Lysosomal Pathway in Neurodegeneration
80%
see_also
📖
Endosomal Sorting Defects in Neurodegeneration
80%
see_also
📖
Neural Circuit Disruption in Neurodegeneration
80%
see_also
📖
Senescent Cell Clearance in Neurodegeneration
80%
see_also
📖
Alzheimer's Disease Biomarkers
80%
see_also
📖
ASL Perfusion Biomarkers for Alzheimer's Disease
80%
see_also
📖
Digital Biomarkers for Alzheimer's Disease
80%
see_also
📖
Dried Blood Spot Biomarker Test for Alzheimer's Disease
80%
see_also
📖
DTI Biomarkers for Alzheimer's Disease
80%
see_also
📖
EEG Biomarkers for Alzheimer's Disease
80%
see_also
📖
Eye-Tracking Digital Markers in Alzheimer's Disease
80%
see_also
📖
Gait Biomarkers for Alzheimer's Disease
80%
see_also
📖
GFAP in Alzheimer's Disease
80%
see_also
📖
Inflammatory Biomarkers in Alzheimer's Disease
80%
see_also
📖
Neurogranin - Alzheimer's Disease Biomarker
80%
see_also
📖
Ocular Fluid Biomarkers for Alzheimer's Disease
80%
see_also
📖
Olfactory Biomarkers for Alzheimer's Disease
80%
see_also
📖
Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'
80%
see_also
📖
Salivary Biomarkers for Alzheimer's Disease
80%
see_also
📖
Sleep Biomarkers for Alzheimer's Disease
80%
see_also
📖
Synaptic Biomarkers for Alzheimer's Disease
80%
see_also
📖
Tear Film Biomarkers in Alzheimer's Disease
80%
see_also
📖
Diffuse Amyloid Deposits in Alzheimer's Disease
80%
see_also
📖
ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)
80%
see_also
📖
ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT056
80%
see_also
📖
BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer
80%
see_also
📖
BMS-986368 Phase 2 - Agitation in Alzheimer's Disease
80%
see_also
📖
BMS-986446 Phase 2 Trial for Early Alzheimer's Disease
80%
see_also
📖
Centella asiatica Phase 1 Trial for Alzheimer's Disease
80%
see_also
📖
Escitalopram for Agitation in Alzheimer's Disease (NCT0
80%
see_also
📖
Fasudil for Early Alzheimer's Disease (FEAD) - NCT06362
80%
see_also
📖
[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea
80%
see_also
📖
Foralumab Phase 2 Trial for Alzheimer's Disease
80%
see_also
📖
GSK4527226 (AL101) for Early Alzheimer's Disease (NCT06
80%
see_also
📖
Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas
80%
see_also
📖
IGC-AD1 for Agitation in Alzheimer's Disease (NCT055436
80%
see_also
📖
ITI-1284 for Alzheimer's Disease Psychosis (NCT06540833
80%
see_also
📖
KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D
80%
see_also
📖
NCT03875638 - Levetiracetam for Alzheimer's Disease
80%
see_also
📖
LHP588: P. gingivalis Targeting for Alzheimer's Disease
80%
see_also
📖
MAR Polypill for Alzheimer's Disease (NCT06597058)
80%
see_also
📖
Masupirdine for Alzheimer's Disease Agitation
80%
see_also
📖
Masupirdine for Agitation in Alzheimer's Disease (NCT05
80%
see_also
📖
MK-2214 for Early Alzheimer's Disease
80%
see_also
📖
Nabilone for Agitation in Alzheimer's Disease (NCT04516
80%
see_also
📖
NAB-IT: Nabilone for Agitation in Alzheimer's Disease
80%
see_also
📖
TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical
80%
see_also
📖
GV1001 for Moderate to Severe Alzheimer's Disease (NCT0
80%
see_also
📖
Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)
80%
see_also
📖
CBD (Cannabidiol) for Alzheimer's Disease Agitation - N
80%
see_also
📖
GSK4527226 (AL101) for Early Alzheimer's Disease (NCT06
80%
see_also
📖
KarXT for Alzheimer's Disease Cognitive Impairment - MI
80%
see_also
📖
NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)
80%
see_also
📖
DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'
80%
see_also
📖
NCT06582706: Nicotinic Acid for Alzheimer's Disease
80%
see_also
📖
NRTIs for Alzheimer's Disease: Targeting Type-I Interfe
80%
see_also
📖
ONO-2020 for Alzheimer's Disease (NCT06881836)
80%
see_also
📖
NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis
80%
see_also
📖
Piromelatine 20 mg for Mild Dementia Due to Alzheimer's
80%
see_also
📖
PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise
80%
see_also
📖
Probiotics in Mild Alzheimer's Disease (NCT06181513)
80%
see_also
📖
Recombinant Human Serum Albumin for Alzheimer's Disease
80%
see_also
📖
Senicapoc Alzheimer's Disease Trial - NCT04804241
80%
see_also
📖
SHR-1707 for Alzheimer's Disease (NCT06199037)
80%
see_also
📖
Siponimod for Alzheimer's Disease (NCT06639282)
80%
see_also
📖
SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime
80%
see_also
📖
SToP-AD: Suvorexant for Alzheimer's Disease Prevention
80%
see_also
📖
CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca
80%
see_also
📖
Cholinergic System Degeneration in Alzheimer's Disease
80%
see_also
📖
EEG Microstates in Alzheimer's Disease
80%
see_also
📖
Glymphatic System in Alzheimer's Disease
80%
see_also
📖
Locus Coeruleus Degeneration in Alzheimer's Disease
80%
see_also
📖
Metal Ion Homeostasis in Alzheimer's Disease
80%
see_also
📖
Neuroinflammation in Alzheimer's Disease
80%
see_also
📖
Sex-Specific Mechanisms in Alzheimer's Disease
80%
see_also
📖
Tau Kinase-Phosphatase Balance in Alzheimer's Disease
80%
see_also
📖
Ubiquitin-Proteasome System Dysfunction in Alzheimer's
80%
see_also
📖
Cannabidiol for Alzheimer's Disease Prevention (NCT0582
80%
see_also
📖
EI-1071 Immunomodulator for Alzheimer's Disease (NCT067
80%
see_also
📖
EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer
80%
see_also
📖
ExPlas — Exercise Plasma Transfusion for Alzheimer's Di
80%
see_also
📖
Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise
80%
see_also
📖
LEAF Trial - THC+CBD for Alzheimer's Disease Agitation
80%
see_also
📖
The Alzheimer's Disease Tau Platform Clinical Trial (NC
80%
see_also
📖
X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer
80%
see_also
📖
Exciva Alzheimer's Disease Phase 2/3 Trial
80%
see_also
📖
NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A
80%
see_also
📖
TRAP-AD: Transcranial Photobiomodulation for Alzheimer'
80%
see_also
📖
VY7523 Phase 1/2 Alzheimer's Disease Trial
80%
see_also
📖
Mitochondrial Dysfunction in Alzheimer's Disease Pathwa
80%
see_also
📖
Neurovascular Dysfunction in Alzheimer's Disease: Integ
80%
see_also
📖
NLRP3 Inflammasome Pathway in Alzheimer's Disease
80%
see_also
📖
Sporadic Alzheimer's Disease Pathway
80%
see_also
📖
Vascular Dementia Mechanisms — Overlap with Alzheimer's
80%
see_also
📖
Master Screening Study to Determine Individuals With Potenti
80%
see_also
📖
Ozanimod for Alzheimer's Disease (NCT06862960)
80%
see_also
📖
Alzheimer's Disease Mechanism Index
80%
see_also
📖
APOE Lipid Metabolism Pathway in Alzheimer's Disease
80%
see_also
📖
Endolysosomal Pathway in Alzheimer's Disease
80%
see_also
📖
Neuroinflammation Hypothesis in Alzheimer's Disease
80%
see_also
📖
Synaptic Loss in Alzheimer's Disease Pathway
80%
see_also
📖
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
80%
see_also
📖
Speech and Cognitive Biomarkers for Alzheimer's Disease
80%
see_also
📖
VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers
80%
see_also
📖
NCT07477431 - Levetiracetam for Persons at Risk for Alzheime
80%
see_also
📖
TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di
80%
see_also
📖
KarXT for Alzheimer's Disease Cognitive Impairment - MI
80%
see_also
📖
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516
80%
see_also
📖
Sleep and Circadian Dysfunction in Alzheimer's Disease
80%
see_also
📖
Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh
80%
see_also
📖
Synaptic Therapy Alzheimer's Research Trial (START): A
80%
see_also
📖
APOE4 and Alzheimer's Disease Risk
80%
see_also
📖
Geniposide for Alzheimer's disease - immune biomarker t
80%
see_also
📖
A Phase 3, Randomised, Double-blinded, Placebo-controlled St
80%
see_also
📖
Rotigotine and Rivastigmine Combination Therapy for Alzheime
80%
see_also
📖
Neuroimaging for Parkinsonian Syndromes (NCT03872102)
80%
see_also
📖
Tau Kinase Signaling Cascade in Alzheimer's Disease
80%
see_also
📖
APOE4 (Apolipoprotein E4)
75%
related
🧪
Cell-Type Specific TREM2 Upregulation in DAM Microglia
72%
related
🧪
GFAP-Positive Reactive Astrocyte Subtype Delineation
72%
related
🧪
Complement C1QA Spatial Gradient in Cortical Layers
72%
related
🧪
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
72%
related
🧪
APOE Isoform Expression Across Glial Subtypes
72%
related
🧪
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
72%
related
🧪
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
72%
related
🧪
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
72%
related
🧫
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
70%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
70%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
70%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
70%
related
🧫
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
70%
see_also
📖
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for
70%
see_also
📖
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392
70%
see_also
📖
nct05508789
65%
see_also
📖
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
65%
see_also
📖
remternetug-anti-amyloid-alzheimers
65%
see_also
📖
APOE2 (Apolipoprotein E2)
65%
see_also
📖
APOE3 (Apolipoprotein E3)
65%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
63%
see_also
📖
al002-trem2-agonist-alzheimers
60%
see_also
📖
MK-1167 Phase 2 AD Trial (MK-1167-008)
60%
see_also
📖
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M
60%
see_also
📖
PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD
60%
see_also
📖
Cross-National Cancer-Dementia Correlation and Shared Diseas
60%
see_also
📖
Cancer-Dementia Inverse Correlation: Epidemiological Evidenc
60%
see_also
📖
SNCA Gene Variants and Mutations
60%
see_also
📖
SNCA — Alpha-Synuclein Gene Entity Page
60%
see_also
📖
Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP
60%
see_also
📖
PSP Liquid-Liquid Phase Separation and Biomolecular Condensa
60%
related
🧫
s:** - Test whether HCN1 knockout specifically in EC layer I
60%
related
🧫
Proposed experiment from debate on Synaptic pruning by micro
60%
related
🧫
Brain Connectivity-Targeted tACS Trial in Early AD
60%
related
🧫
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
60%
related
🧫
4R-Tau Targeting Therapies for PSP and CBS
60%
related
🧫
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
60%
related
🧫
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
60%
related
🧫
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
60%
related
🧫
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
60%
related
🧫
Animal Model Comparison for Neurodegenerative Disease Therap
60%
related
🧫
Anti-Tau Immunotherapy Dosing Optimization
60%
related
🧫
ApoE4 Function in Alzheimer's Disease
60%
related
🧫
Experiment: Autoimmune Hypothesis Testing in AD
60%
related
🧫
Autophagy Enhancement Drug Screening for Neurodegeneration
60%
related
🧫
Biomarker-Guided Sequential Therapy Selection in Alzheimer
60%
related
🧫
Blood-Based Biomarker Panel for Early AD Detection
60%
related
🧫
tACS Connectivity Trial in Early Alzheimer's
60%
related
🧫
Brain Connectivity-Targeted tACS Trial in Early AD
60%
related
🧫
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated
60%
related
🧫
Cognitive Reserve Mechanisms in Alzheimer's Disease — M
60%
related
🧫
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
60%
related
🧫
Down Syndrome Alzheimer's Disease: Mechanisms and Thera
60%
related
🧫
Epigenetic Regulation Dysfunction in Alzheimer's and Pa
60%
related
🧫
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
60%
related
🧫
Gap Junction Dysfunction Validation in Parkinson's Dise
60%
related
🧫
Lifestyle Intervention Mechanisms in Alzheimer's Diseas
60%
related
🧫
Metal Ion Homeostasis Dysregulation in Alzheimer's Dise
60%
related
🧫
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech
60%
related
🧫
Microglial Aging and Immune Memory in Neurodegeneration — Tr
60%
related
🧫
Migraine Cortical Hyperexcitability and Alzheimer's Dis
60%
related
🧫
Mixed Pathology Effects on Parkinson's Disease Progress
60%
related
🧫
Neural Stem Cell Therapy for Alzheimer's Disease
60%
related
🧫
Normal Aging to Alzheimer's Disease Transition Trigger
60%
related
🧫
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
60%
related
🧫
Prion Strain Diversity and Selective Vulnerability
60%
related
🧫
SCFA-Mediated Neuroinflammation in Alzheimer's Disease
60%
related
🧫
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer
60%
related
🧫
Sex Differences in Alzheimer's Disease — mechanisms and
60%
related
🧫
Sleep Disruption and Alzheimer's Disease — mechanism an
60%
related
🧫
Traumatic Brain Injury and Alzheimer's Disease Relation
60%
related
🧫
Experiment Validation: In vitro ThT Assay
60%
related
🧫
Tau ASO Therapy
60%
related
🧫
Microglial TREM2 Agonist In Vivo Efficacy
60%
related
🧫
TREM2 Function in Alzheimer's Disease — From Risk Varia
60%
related
🧫
Vascular Contribution to Alzheimer's Disease — Beyond A
60%
related
🧫
Vascular Contributions to Alzheimer Disease and Mixed Pathol
60%
related
🧫
Viral Infections and Alzheimer's Disease — causal mecha
60%
related
🧫
Proposed experiment from debate on Astrocytes adopt A1 (neur
60%
related
🧫
s:** - Biochemical binding assays measuring PROTAC selectivi
60%
related
🧫
Proposed experiment from debate on Epigenetic clocks and bio
60%
related
🧫
Proposed experiment from debate on Microglia activate astroc
60%
related
🧫
Proposed experiment from debate on Astrocytes adopt A1 (neur
60%
related
🧫
Proposed experiment from debate on Epigenetic clocks and bio
60%
related
🧫
s:** - Temporal analysis showing mitochondrial defects prece
60%
related
🧫
s:** - Test MCU overexpression specifically in layer II neur
60%
related
🧫
Proposed experiment from debate on TDP-43 undergoes liquid-l
60%
related
🧫
Proposed experiment from debate on TDP-43 undergoes liquid-l
60%
related
🧫
s:** - Compare uptake with/without magnetic particles using
60%
related
🧫
Proposed experiment from debate on Perivascular spaces and g
60%
related
🧫
s:** - Test tau spreading in AQP4 knockout vs wild-type mice
60%
related
🧫
Proposed experiment from debate on Mitochondrial transfer be
60%
related
🧫
s:** - Compare tau strain spreading in EXT1/EXT2 conditional
60%
related
🧫
Proposed experiment from debate on Perivascular spaces and g
60%
related
🧫
Proposed experiment from debate on Mitochondrial transfer be
60%
related
🧫
s:** - Dose-response studies showing therapeutic window with
60%
related
🧫
Proposed experiment from debate on Senolytics targeting p16/
60%
related
🧫
Biomechanical Impact Profiles and Chronic Traumatic Encephal
60%
related
🧫
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
60%
related
🧫
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
60%
related
🧫
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
60%
related
🧫
Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Tr
60%
related
🧫
DLB Cognitive Fluctuation Mechanism Experiment
60%
related
🧫
Genetic Risk Modifiers in DLB Phenotype
60%
related
🧫
Tau Co-Pathology in DLB Clinical Heterogeneity
60%
related
🧫
DLB Treatment Response Biomarkers — Predicting Cholinesteras
60%
related
🧫
Selective Vulnerability of Dopaminergic Neurons — Mechanism
60%
related
🧫
Epigenetic Clocks in Neurodegeneration — Causal Drivers or P
60%
related
🧫
Epigenetic Dysregulation in Huntington's Disease — Ther
60%
related
🧫
Experiment Index
60%
related
🧫
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
60%
related
🧫
GLP-1 Agonist Responder Prediction Study — Precision Medicin
60%
related
🧫
Iron Dyshomeostasis in MSA Pathogenesis Experiment
60%
related
🧫
Levodopa-Induced Dyskinesias Mechanism — Experiment Design
60%
related
🧫
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
60%
related
🧫
Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic
60%
related
🧫
NPH Glymphatic System Interaction Experiment
60%
related
🧫
Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
60%
related
🧫
Prion Strain Diversity and Selective Vulnerability in CJD
60%
related
🧫
Protein Aggregation Kinetic Validation Results
60%
related
🧫
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
60%
related
🧫
Experiment Scoring Methodology
60%
related
🧫
Selective Neuronal Vulnerability to Aging — Mapping Why Spec
60%
related
🧫
Sleep and Circadian Dysfunction as Driver of Neurodegenerati
60%
related
🧫
Tau Pathology Initiation Zone Identification
60%
related
🧫
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
60%
related
🧫
Tau Propagation Causality Test — Does Tau Spread Drive Neuro
60%
related
🧫
Tau Spreading Network Mapping via Spatial Transcriptomics in
60%
related
🧫
Biomechanical Impact Profiles and Chronic Traumatic Encephal
60%
related
🧫
TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an
60%
related
🧫
Wilson Disease Neurodegeneration: Mechanism and Therapeutic
60%
see_also
📖
ABCA1 - ATP-Binding Cassette Transporter A1
60%
see_also
📖
ABCA7 (Redirect)
60%
related
🧪
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
55%
see_also
📖
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
55%
see_also
📖
Long-term Effects of Hearing Intervention on Brain Health in
55%
see_also
📖
ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal
55%
see_also
📖
Shared Mechanisms Between Alzheimer and Parkinson Disease
55%
see_also
📖
Blood-Brain Barrier Dysfunction and Therapeutic Delivery for
55%
see_also
📖
Multimodal Diagnostic Algorithm for CBS and PSP
55%
see_also
📖
Neuroinflammation in Parkinson's Disease Dementia and D
55%
see_also
📖
Synaptic Loss and Dysfunction Pathway
55%
see_also
📖
Systemic Infection and Tau Pathology Acceleration
55%
see_also
📖
Tau Seeding and Propagation Pathway
55%
related
🧫
s:** - Test whether HCN1 knockout specifically in EC layer I
54%
related
🧫
Proposed experiment from debate on Synaptic pruning by micro
54%
related
🧫
Brain Connectivity-Targeted tACS Trial in Early AD
54%
related
🧫
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
54%
related
🧫
4R-Tau Targeting Therapies for PSP and CBS
54%
related
🧫
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
54%
related
🧫
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
54%
related
🧫
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
54%
related
🧫
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
54%
related
🧫
Animal Model Comparison for Neurodegenerative Disease Therap
54%
related
🧫
Anti-Tau Immunotherapy Dosing Optimization
54%
related
🧫
ApoE4 Function in Alzheimer's Disease
54%
related
🧫
Experiment: Autoimmune Hypothesis Testing in AD
54%
related
🧫
Autophagy Enhancement Drug Screening for Neurodegeneration
54%
related
🧫
Biomarker-Guided Sequential Therapy Selection in Alzheimer
54%
related
🧫
Blood-Based Biomarker Panel for Early AD Detection
54%
related
🧫
tACS Connectivity Trial in Early Alzheimer's
54%
related
🧫
Brain Connectivity-Targeted tACS Trial in Early AD
54%
related
🧫
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated
54%
related
🧫
Cognitive Reserve Mechanisms in Alzheimer's Disease — M
54%
related
🧫
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
54%
related
🧫
Down Syndrome Alzheimer's Disease: Mechanisms and Thera
54%
related
🧫
Epigenetic Regulation Dysfunction in Alzheimer's and Pa
54%
related
🧫
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
54%
related
🧫
Gap Junction Dysfunction Validation in Parkinson's Dise
54%
related
🧫
Lifestyle Intervention Mechanisms in Alzheimer's Diseas
54%
related
🧫
Metal Ion Homeostasis Dysregulation in Alzheimer's Dise
54%
related
🧫
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech
54%
related
🧫
Microglial Aging and Immune Memory in Neurodegeneration — Tr
54%
related
🧫
Migraine Cortical Hyperexcitability and Alzheimer's Dis
54%
related
🧫
Mixed Pathology Effects on Parkinson's Disease Progress
54%
related
🧫
Neural Stem Cell Therapy for Alzheimer's Disease
54%
related
🧫
Normal Aging to Alzheimer's Disease Transition Trigger
54%
related
🧫
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
54%
related
🧫
Prion Strain Diversity and Selective Vulnerability
54%
related
🧫
SCFA-Mediated Neuroinflammation in Alzheimer's Disease
54%
related
🧫
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer
54%
related
🧫
Sex Differences in Alzheimer's Disease — mechanisms and
54%
related
🧫
Sleep Disruption and Alzheimer's Disease — mechanism an
54%
related
🧫
Traumatic Brain Injury and Alzheimer's Disease Relation
54%
related
🧫
Experiment Validation: In vitro ThT Assay
54%
related
🧫
Tau ASO Therapy
54%
related
🧫
Microglial TREM2 Agonist In Vivo Efficacy
54%
related
🧫
TREM2 Function in Alzheimer's Disease — From Risk Varia
54%
related
🧫
Vascular Contribution to Alzheimer's Disease — Beyond A
54%
related
🧫
Vascular Contributions to Alzheimer Disease and Mixed Pathol
54%
related
🧫
Viral Infections and Alzheimer's Disease — causal mecha
54%
related
🧫
Proposed experiment from debate on Astrocytes adopt A1 (neur
54%
related
🧫
s:** - Biochemical binding assays measuring PROTAC selectivi
54%
related
🧫
Proposed experiment from debate on Epigenetic clocks and bio
54%
related
🧫
Proposed experiment from debate on Microglia activate astroc
54%
related
🧫
Proposed experiment from debate on Astrocytes adopt A1 (neur
54%
related
🧫
Proposed experiment from debate on Epigenetic clocks and bio
54%
related
🧫
s:** - Temporal analysis showing mitochondrial defects prece
54%
related
🧫
s:** - Test MCU overexpression specifically in layer II neur
54%
related
🧫
Proposed experiment from debate on TDP-43 undergoes liquid-l
54%
related
🧫
Proposed experiment from debate on TDP-43 undergoes liquid-l
54%
related
🧫
s:** - Compare uptake with/without magnetic particles using
54%
related
🧫
Proposed experiment from debate on Perivascular spaces and g
54%
related
🧫
s:** - Test tau spreading in AQP4 knockout vs wild-type mice
54%
related
🧫
Proposed experiment from debate on Mitochondrial transfer be
54%
related
🧫
s:** - Compare tau strain spreading in EXT1/EXT2 conditional
54%
related
🧫
Proposed experiment from debate on Perivascular spaces and g
54%
related
🧫
Proposed experiment from debate on Mitochondrial transfer be
54%
related
🧫
s:** - Dose-response studies showing therapeutic window with
54%
related
🧫
Proposed experiment from debate on Senolytics targeting p16/
54%
related
🧫
Biomechanical Impact Profiles and Chronic Traumatic Encephal
54%
related
🧫
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
54%
related
🧫
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
54%
related
🧫
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
54%
related
🧫
Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Tr
54%
related
🧫
DLB Cognitive Fluctuation Mechanism Experiment
54%
related
🧫
Genetic Risk Modifiers in DLB Phenotype
54%
related
🧫
Tau Co-Pathology in DLB Clinical Heterogeneity
54%
related
🧫
DLB Treatment Response Biomarkers — Predicting Cholinesteras
54%
related
🧫
Selective Vulnerability of Dopaminergic Neurons — Mechanism
54%
related
🧫
Epigenetic Clocks in Neurodegeneration — Causal Drivers or P
54%
related
🧫
Epigenetic Dysregulation in Huntington's Disease — Ther
54%
related
🧫
Experiment Index
54%
related
🧫
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
54%
related
🧫
GLP-1 Agonist Responder Prediction Study — Precision Medicin
54%
related
🧫
Iron Dyshomeostasis in MSA Pathogenesis Experiment
54%
related
🧫
Levodopa-Induced Dyskinesias Mechanism — Experiment Design
54%
related
🧫
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
54%
related
🧫
Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic
54%
related
🧫
NPH Glymphatic System Interaction Experiment
54%
related
🧫
Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
54%
related
🧫
Prion Strain Diversity and Selective Vulnerability in CJD
54%
related
🧫
Protein Aggregation Kinetic Validation Results
54%
related
🧫
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
54%
related
🧫
Experiment Scoring Methodology
54%
related
🧫
Selective Neuronal Vulnerability to Aging — Mapping Why Spec
54%
related
🧫
Sleep and Circadian Dysfunction as Driver of Neurodegenerati
54%
related
🧫
Tau Pathology Initiation Zone Identification
54%
related
🧫
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
54%
related
🧫
Tau Propagation Causality Test — Does Tau Spread Drive Neuro
54%
related
🧫
Tau Spreading Network Mapping via Spatial Transcriptomics in
54%
related
🧫
Biomechanical Impact Profiles and Chronic Traumatic Encephal
54%
related
🧫
TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an
54%
related
🧫
Wilson Disease Neurodegeneration: Mechanism and Therapeutic
54%
mentions
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
50%
mentions
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
50%
mentions
🧪
Temporal Decoupling via Circadian Clock Reset
50%
mentions
🧪
Netrin-1 Gradient Restoration
50%
mentions
🧪
Smartphone-Detected Motor Variability Correction
50%
mentions
🧪
Purinergic Signaling Polarization Control
50%
mentions
🧪
Mitochondrial-Lysosomal Contact Site Engineering
50%
mentions
🧪
Osmotic Gradient Restoration via Selective AQP1 Enhancement
50%
mentions
🧪
Circadian-Synchronized Proteostasis Enhancement
50%
mentions
🧪
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
50%
mentions
🧪
Selective HDAC3 Inhibition with Cognitive Enhancement
50%
mentions
🧪
HSP90-Tau Disaggregation Complex Enhancement
50%
mentions
🧪
Selective APOE4 Degradation via Proteolysis Targeting Chimer
50%
mentions
🧪
Ganglioside Rebalancing Therapy
50%
mentions
🧪
Mitochondrial SPM Synthesis Platform Engineering
50%
mentions
🧪
CX43 hemichannel engineering enables size-selective mitochon
50%
mentions
🧪
VCP-Mediated Autophagy Enhancement
50%
mentions
🧪
Arginine Methylation Enhancement Therapy
50%
mentions
🧪
SASP-Mediated Cholinergic Synapse Disruption
50%
mentions
🧪
Mitochondrial RNA Granule Rescue Pathway
50%
mentions
🧪
Multi-Modal Stress Response Harmonization
50%
mentions
🧪
Complement C1q Mimetic Decoy Therapy
50%
mentions
🧪
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
50%
mentions
🧪
RAB27A-dependent extracellular vesicle engineering for mitoc
50%
mentions
🧪
CYP46A1 Overexpression Gene Therapy
50%
mentions
🧪
Enteric Nervous System Prion-Like Propagation Blockade
50%
mentions
🧪
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
50%
mentions
🧪
Retinal Vascular Microcirculation Rescue
50%
mentions
🧪
Metabolic Reprogramming via Microglial Glycolysis Inhibition
50%
mentions
🧪
Astroglial Gap Junction Coordination via Connexin-43 Phospho
50%
mentions
🧪
Metabolic Circuit Breaker via Lipid Droplet Modulation
50%
mentions
🧪
Noradrenergic-Tau Propagation Blockade
50%
mentions
🧪
Adenosine-Astrocyte Metabolic Reset
50%
mentions
🧪
AMPK hypersensitivity in astrocytes creates enhanced mitocho
50%
mentions
🧪
APOE4 Allosteric Rescue via Small Molecule Chaperones
50%
mentions
🧪
Palmitoylation-Targeted BACE1 Trafficking Disruptors
50%
mentions
🧪
Microglial Efferocytosis Enhancement via GPR32 Superagonists
50%
mentions
🧪
Biorhythmic Interference via Controlled Sleep Oscillations
50%
mentions
🧪
Quantum Coherence Disruption in Cellular Communication
50%
mentions
🧪
Nutrient-Sensing Epigenetic Circuit Reactivation
50%
mentions
🧪
LRP1-Dependent Tau Uptake Disruption
50%
mentions
🧪
Cryptic Exon Silencing Restoration
50%
mentions
🧪
SIRT6-NAD+ Axis Enhancement Therapy
50%
mentions
🧪
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
50%
mentions
🧪
Extracellular Vesicle Biogenesis Modulation
50%
mentions
🧪
Circadian Rhythm Entrainment of Reactive Astrocytes
50%
mentions
🧪
SASP-Mediated Complement Cascade Amplification
50%
mentions
🧪
Complement C1q Subtype Switching
50%
mentions
🧪
Microglial Purinergic Reprogramming
50%
mentions
🧪
Heat Shock Protein 70 Disaggregase Amplification
50%
mentions
🧪
Autophagosome Maturation Checkpoint Control
50%
mentions
🧪
Glymphatic System-Enhanced Antibody Clearance Reversal
50%
mentions
🧪
Prefrontal sensory gating circuit restoration via PV interne
50%
mentions
🧪
Chaperone-Mediated APOE4 Refolding Enhancement
50%
mentions
🧪
Sphingolipid Metabolism Reprogramming
50%
mentions
🧪
PARP1 Inhibition Therapy
50%
mentions
🧪
Low Complexity Domain Cross-Linking Inhibition
50%
mentions
🧪
Ocular Immune Privilege Extension
50%
mentions
🧪
Hypocretin-Neurogenesis Coupling Therapy
50%
mentions
🧪
Gut Barrier Permeability-α-Synuclein Axis Modulation
50%
mentions
🧪
GAP43-mediated tunneling nanotube stabilization enhances neu
50%
mentions
🧪
Extracellular Matrix Stiffness Modulation
50%
mentions
🧪
Synaptic Vesicle Tau Capture Inhibition
50%
mentions
🧪
Pericyte Contractility Reset via Selective PDGFR-β Agonism
50%
mentions
🧪
Microbial Metabolite-Mediated α-Synuclein Disaggregation
50%
mentions
🧪
Perforant Path Presynaptic Terminal Protection Strategy
50%
mentions
🧪
Optogenetic Microglial Deactivation via Engineered Inhibitor
50%
mentions
🧪
DNMT1-Targeting Antisense Oligonucleotide Reset
50%
mentions
🧪
Senescence-Induced Lipid Peroxidation Spreading
50%
mentions
🧪
Piezoelectric Nanochannel BBB Disruption
50%
mentions
🧪
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
50%
mentions
🧪
Lipid Droplet Dynamics as Phenotype Switches
50%
mentions
🧪
Circadian-Synchronized LRP1 Pathway Activation
50%
mentions
🧪
Glycine-Rich Domain Competitive Inhibition
50%
mentions
🧪
SASP-Driven Aquaporin-4 Dysregulation
50%
mentions
🧪
Axonal RNA Transport Reconstitution
50%
mentions
🧪
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
50%
mentions
🧪
Circadian-Gated Maresin Biosynthesis Amplification
50%
mentions
🧪
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
50%
mentions
🧪
KDM6A-Mediated H3K27me3 Rejuvenation
50%
mentions
🧪
Lysosomal Membrane Repair Enhancement
50%
mentions
🧪
Sleep Spindle-Synaptic Plasticity Enhancement
50%
mentions
🧪
Lysosomal Calcium Channel Modulation Therapy
50%
mentions
🧪
Astrocyte-Mediated Neuronal Epigenetic Rescue
50%
mentions
🧪
Blood-Brain Barrier SPM Shuttle System
50%
mentions
🧪
Mitochondrial Transfer Pathway Enhancement
50%
mentions
🧪
Stress Granule Phase Separation Modulators
50%
mentions
🧪
TFAM overexpression creates mitochondrial donor-recipient gr
50%
mentions
🧪
Interfacial Lipid Mimetics to Disrupt Domain Interaction
50%
mentions
🧪
Pharmacological Enhancement of APOE4 Glycosylation
50%
mentions
🧪
Membrane Cholesterol Gradient Modulators
50%
mentions
🧪
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
50%
mentions
🧪
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
50%
mentions
🧪
Flotillin-1 Stabilization Compounds
50%
mentions
🧪
Metabolic Switch Targeting for A1→A2 Repolarization
50%
mentions
🧪
Targeted APOE4-to-APOE3 Base Editing Therapy
50%
mentions
🧪
Temporal TET2-Mediated Hydroxymethylation Cycling
50%
mentions
🧪
HDAC3-Selective Inhibition for Clock Reset
50%
mentions
🧪
Magnetosonic-Triggered Transferrin Receptor Clustering
50%
mentions
🧪
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
50%
mentions
🧪
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
50%
mentions
🧪
Chromatin Accessibility Restoration via BRD4 Modulation
50%
mentions
🧪
Transcriptional Autophagy-Lysosome Coupling
50%
mentions
🧪
Digital Twin-Guided Metabolic Reprogramming
50%
mentions
🧪
Lysosomal Positioning Dynamics Modulation
50%
mentions
🧪
Lysosomal Enzyme Trafficking Correction
50%
mentions
🧪
Circadian Clock-Autophagy Synchronization
50%
mentions
🧪
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
50%
mentions
🧪
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
50%
mentions
🧪
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
50%
mentions
🧪
Senescence-Associated Myelin Lipid Remodeling
50%
mentions
🧪
Gamma entrainment therapy to restore hippocampal-cortical sy
50%
mentions
🧪
Glial Glycocalyx Remodeling Therapy
50%
mentions
🧪
R-Loop Resolution Enhancement Therapy
50%
mentions
🧪
Aquaporin-4 Polarization Rescue
50%
mentions
🧪
Senescence-Activated NAD+ Depletion Rescue
50%
mentions
🧪
Competitive APOE4 Domain Stabilization Peptides
50%
mentions
🧪
Epigenetic Memory Erasure via TET2 Activation
50%
mentions
🧪
Reelin-Mediated Cytoskeletal Stabilization Protocol
50%
mentions
🧪
HCN1-Mediated Resonance Frequency Stabilization Therapy
50%
mentions
🧪
TET2-Mediated Demethylation Rejuvenation Therapy
50%
mentions
🧪
Mechanosensitive Ion Channel Reprogramming
50%
mentions
🧪
Serine/Arginine-Rich Protein Kinase Modulation
50%
mentions
🧪
Selective Acid Sphingomyelinase Modulation Therapy
50%
mentions
🧪
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
50%
mentions
🧪
Vocal Cord Neuroplasticity Stimulation
50%
mentions
🧪
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
50%
mentions
🧪
Synthetic Biology Rewiring via Orthogonal Receptors
50%
mentions
🧪
Ephrin-B2/EphB4 Axis Manipulation
50%
mentions
🧪
Microbial Inflammasome Priming Prevention
50%
mentions
🧪
Phase-Separated Organelle Targeting
50%
mentions
🧪
Nucleolar Stress Response Normalization
50%
mentions
🧪
Vagal Afferent Microbial Signal Modulation
50%
mentions
🧪
Cross-Seeding Prevention Strategy
50%
mentions
🧪
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
50%
mentions
🧪
Purinergic P2Y12 Inverse Agonist Therapy
50%
mentions
🧪
Microbiome-Derived Tryptophan Metabolite Neuroprotection
50%
mentions
🧪
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
50%
mentions
🧪
Near-infrared light therapy stimulates COX4-dependent mitoch
50%
mentions
🧪
FOXO3-Longevity Pathway Epigenetic Reprogramming
50%
mentions
🧪
Trans-Synaptic Adhesion Molecule Modulation
50%
mentions
🧪
Sphingomyelin Synthase Activators for Raft Remodeling
50%
mentions
🧪
RNA Granule Nucleation Site Modulation
50%
mentions
🔬
What are the mechanisms underlying selective vulnerability o
50%
mentions
🔬
What are the mechanisms underlying 4r-tau strain-specific sp
50%
mentions
🔬
What are the mechanisms underlying tdp-43 phase separation t
50%
mentions
🔬
What are the mechanisms underlying blood-brain barrier trans
50%
mentions
🔬
What are the mechanisms underlying apoe4 structural biology
50%
mentions
🔬
What are the mechanisms underlying autophagy-lysosome pathwa
50%
mentions
🔬
What are the mechanisms underlying neuroinflammation resolut
50%
mentions
🔬
What are the mechanisms underlying rna binding protein dysre
50%
mentions
🔬
What are the mechanisms underlying mitochondrial transfer be
50%
mentions
🔬
What are the mechanisms underlying perivascular spaces and g
50%
mentions
🔬
Epigenetic reprogramming in aging neurons
50%
mentions
🔬
Extracellular vesicle biomarkers for early AD detection
50%
mentions
🔬
Senescent cell clearance as neurodegeneration therapy
50%
mentions
🔬
Investigate prion-like spreading of tau pathology through co
50%
mentions
🔬
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
50%
related
🔬
What are the mechanisms underlying 4r-tau strain-specific sp
50%
related
🔬
What are the mechanisms underlying tdp-43 phase separation t
50%
related
🔬
What are the mechanisms underlying astrocyte reactivity subt
50%
related
🔬
What are the mechanisms underlying blood-brain barrier trans
50%
related
🔬
What are the mechanisms underlying microglia-astrocyte cross
50%
related
🔬
What are the mechanisms underlying apoe4 structural biology
50%
related
🔬
What are the mechanisms underlying autophagy-lysosome pathwa
50%
related
🔬
What are the mechanisms underlying digital biomarkers and ai
50%
related
🔬
What are the mechanisms underlying senolytic therapy for age
50%
related
🔬
What are the mechanisms underlying neuroinflammation resolut
50%
related
🔬
What are the mechanisms underlying what are the mechanisms b
50%
related
🔬
Investigate how lipid raft composition (cholesterol metaboli
50%
related
🔬
What are the mechanisms underlying sleep disruption as cause
50%
related
🔬
What are the mechanisms underlying rna binding protein dysre
50%
related
🔬
What are the mechanisms underlying synaptic pruning by micro
50%
related
🔬
What are the mechanisms underlying mitochondrial transfer be
50%
related
🔬
What are the mechanisms underlying epigenetic clocks and bio
50%
related
🔬
What are the mechanisms underlying perivascular spaces and g
50%
related
🔬
Analyze circuit-level changes in neurodegeneration using All
50%
related
🔬
Epigenetic reprogramming in aging neurons
50%
related
🔬
Investigate prion-like spreading of tau pathology through co
50%
related
🔬
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
50%
related
🔬
Which cell types show the most significant expression change
50%
related
🔬
The disease-associated microglia (DAM) phenotype involves TR
50%
related
🔬
What are the mechanisms underlying selective vulnerability o
50%
related
🔬
What are the mechanisms underlying 4r-tau strain-specific sp
50%
related
🔬
What are the mechanisms underlying tdp-43 phase separation t
50%
related
🔬
What are the mechanisms underlying astrocyte reactivity subt
50%
related
🔬
What are the mechanisms underlying blood-brain barrier trans
50%
related
🔬
What are the mechanisms underlying microglia-astrocyte cross
50%
related
🔬
What are the mechanisms underlying apoe4 structural biology
50%
related
🔬
What are the mechanisms underlying autophagy-lysosome pathwa
50%
related
🔬
What are the mechanisms underlying digital biomarkers and ai
50%
related
🔬
What are the mechanisms underlying senolytic therapy for age
50%
related
🔬
What are the mechanisms underlying neuroinflammation resolut
50%
related
🔬
What are the mechanisms underlying what are the mechanisms b
50%
related
🔬
What are the mechanisms underlying what are the mechanisms b
50%
related
🔬
What are the mechanisms underlying mechanistic role of apoe
50%
related
🔬
Investigate how lipid raft composition (cholesterol metaboli
50%
related
🔬
What are the mechanisms underlying sleep disruption as cause
50%
related
🔬
What are the mechanisms underlying rna binding protein dysre
50%
related
🔬
What are the mechanisms underlying synaptic pruning by micro
50%
related
🔬
What are the mechanisms underlying mitochondrial transfer be
50%
related
🔬
What are the mechanisms underlying epigenetic clocks and bio
50%
related
🔬
What are the mechanisms underlying perivascular spaces and g
50%
related
🔬
Analyze circuit-level changes in neurodegeneration using All
50%
related
🔬
The disease-associated microglia (DAM) phenotype involves TR
50%
related
🔬
Epigenetic reprogramming in aging neurons
50%
related
🔬
Extracellular vesicle biomarkers for early AD detection
50%
related
🔬
Comprehensive analysis of immune cell subtypes in neurodegen
50%
related
🔬
Analyze the spectrum of microglial activation states (DAM, h
50%
related
🔬
What cell types are most vulnerable in Alzheimers Disease ba
50%
related
🔬
What cell types are most vulnerable in Alzheimer's Dise
50%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
50%
related
🔬
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
50%
related
🔬
Senescent cell clearance as neurodegeneration therapy
50%
related
🔬
Investigate prion-like spreading of tau pathology through co
50%
related
🔬
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
50%
related
🔬
What are the most promising therapeutic strategies for targe
50%
related
🔬
How to break the GBA-alpha-synuclein bidirectional loop for
50%
related
🔬
Can gut-brain axis modulation prevent or slow Alzheimer'
50%
related
🔬
Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph
50%
related
🔬
Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea
50%
related
🔬
Senolytics targeting p16/p21+ senescent astrocytes and micro
50%
related
🔬
Synaptic pruning by microglia in early AD
50%
see_also
📖
p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre
50%
see_also
📖
Digital Therapeutic Platform for Swallowing and Drooling Pro
50%
see_also
📖
Utilisation of Health Services and Quality of Life in Atypic
50%
see_also
📖
Phase 3 Study to Compare the Efficacy and Safety of Masitini
50%
see_also
📖
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month
50%
see_also
📖
A Multicenter, Phase III, Randomized, Double Blind, Placebo-
50%
see_also
📖
A 6-month & 18-month Prospective, Randomized, Placebo-co
50%
see_also
📖
PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr
50%
see_also
📖
Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi
50%
see_also
📖
CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc
50%
see_also
📖
Hereditary Sensory and Autonomic Neuropathy (HSAN)
50%
see_also
📖
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid
50%
see_also
📖
Mirror Therapy and Sensory Re-education in Corticobasal Synd
50%
see_also
📖
Physical and Occupational Therapy in Corticobasal Syndrome
50%
see_also
📖
Healthcare Economics and Cost of Illness in Progressive Supr
50%
see_also
📖
PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O
50%
see_also
📖
Rigidity in Corticobasal Syndrome
50%
see_also
📖
Speech Therapy and Communication Aids in Corticobasal Syndro
50%
see_also
📖
Braak Staging and Tau Propagation Pathway
50%
see_also
📖
C9orf72 Repeat Expansions in CBS and PSP
50%
see_also
📖
Myoclonus and Cortical Hyperexcitability in Corticobasal Syn
50%
see_also
📖
CBS/PSP Panxoneopathy and Membrane Biology
50%
see_also
📖
FTLD-TDP Subtypes and Mechanisms
50%
see_also
📖
GBA Glucocerebrosidase Dysfunction and Parkinson's Dise
50%
see_also
📖
Glial Tau Pathology in PSP and CBD
50%
see_also
📖
Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova
50%
see_also
📖
Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath
50%
see_also
📖
mTOR Signaling in Autophagy and Lysosomal Function
50%
see_also
📖
Neuroresilience Mechanisms and Evidence
50%
see_also
📖
Pesticides and Parkinson Disease (Pest-PD) — NCT06420310
50%
see_also
📖
Advanced Proteolysis and Ubiquitin System Targeting in CBS/P
50%
see_also
📖
HLA Haplotypes and Neuroinflammatory Profiles in PSP
50%
see_also
📖
Metabolic Dysfunction and Insulin Resistance in Progressive
50%
see_also
📖
ALS Therapeutic Landscape — Programs by Phase and Modality
50%
mentions
🧪
TREM2 Conformational Stabilizers for Synaptic Discrimination
48%
mentions
🧪
TREM2-mediated microglial tau clearance enhancement
48%
see_also
📖
AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration
45%
see_also
📖
Alpha-Synuclein PET Imaging and Biomarker Advances
45%
see_also
📖
Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)
45%
see_also
📖
Aquaporin-4 (AQP4) - Glymphatic System Biomarker
45%
see_also
📖
BDNF - Neurotrophic Factor Biomarker
45%
see_also
📖
Imaging Biomarkers for Corticobasal Syndrome and Progressive
45%
see_also
📖
Multi-Analyte Biomarker Panel for Parkinson's Disease D
45%
see_also
📖
Polygenic Risk Score Integration Panel for Alzheimer's
45%
see_also
📖
CSF and Blood Biomarkers in Progressive Supranuclear Palsy
45%
see_also
📖
sTREM2 (Soluble TREM2) - Microglial Biomarker
45%
see_also
📖
sTREM2 (Soluble TREM2) - Biomarker
45%
see_also
📖
BLAAC PD - Black and African Americans Connections to PD (NC
45%
see_also
📖
Clostridium Butyricum for Motor and Non-motor Symptoms in Pa
45%
see_also
📖
CNversyt and Megan Rodden ALS Trials
45%
see_also
📖
Cognitive and Speech Rehabilitation in CBS (NCT05823421)
45%
see_also
📖
DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulat
45%
see_also
📖
Donanemab TRAILBLAZER-ALZ 2 Trial
45%
see_also
📖
First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)
45%
see_also
📖
Gait Analysis Parameter and Upper Limb Evaluation in Neurolo
45%
see_also
📖
Gait and Upper Limb Evaluation in PSP (NCT07136844)
45%
see_also
📖
GBA Brain Molecular Imaging and Blood Biomarkers for Precisi
45%
see_also
📖
Safety and Clinical Outcomes Study: Amniotic and Umbilical C
45%
see_also
📖
A Phase III, Randomized, Double-Blind, Placebo-Controlled, M
45%
see_also
📖
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C
45%
see_also
📖
A Phase 3, Randomized, Double-blind, Placebo-controlled, Par
45%
see_also
📖
Whole-Body Photobiomodulation for Motor and Cognitive Change
45%
see_also
📖
Quality of Life and Caregiver Burden in PSP (NCT03638505)
45%
see_also
📖
Silymarin for Neuroprotection and Symptom Management in Park
45%
see_also
📖
Social Behaviors and Quality of Life in Parkinson's Dis
45%
see_also
📖
Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par
45%
see_also
📖
Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT07170
45%
see_also
📖
UB-311 Alzheimer's Vaccination Trial
45%
see_also
📖
alexander-disease
45%
see_also
📖
Alexander Disease Genetic Variants
45%
see_also
📖
ATP13A9 and Parkinson's Disease
45%
see_also
📖
Callosal Disconnection and Interhemispheric Dysfunction in C
45%
see_also
📖
Caregiver Burden and Support in Corticobasal Syndrome
45%
see_also
📖
Caregiver Support and Palliative Care in Atypical [Parkinson
45%
see_also
📖
Clinical Phenotypes and Subtypes of Corticobasal Syndrome
45%
see_also
📖
Natural History and Prognosis of Corticobasal Syndrome
45%
see_also
📖
Dysphagia and Nutritional Management in Corticobasal Syndrom
45%
see_also
📖
Environmental Toxins and Parkinson's Risk
45%
see_also
📖
HIV-Associated Neurocognitive Disorders (HAND)
45%
see_also
📖
Hemiballismus and Hemichorea in Corticobasal Syndrome
45%
see_also
📖
Investment Landscape: ALS
45%
see_also
📖
Investment Landscape: Frontotemporal Dementia
45%
see_also
📖
Investment Landscape: Huntington's Disease
45%
see_also
📖
Investment Landscape: Parkinson's Disease
45%
see_also
📖
Japanese and German Case Series in Corticobasal Degeneration
45%
see_also
📖
Jervell and Lange-Nielsen Syndrome
45%
see_also
📖
LRRK2 Gene Variants and Mutations
45%
see_also
📖
Nutritional Support and Dietary Interventions in Corticobasa
45%
see_also
📖
Postural Dysfunction and Abnormalities in Corticobasal Syndr
45%
see_also
📖
Pseudobulbar Affect and Emotional Lability in Corticobasal S
45%
see_also
📖
Quality of Life and Caregiver Burden in Progressive Supranuc
45%
see_also
📖
Speech and Voice Disorders in PSP
45%
see_also
📖
Sandhoff Disease
45%
see_also
📖
Sialorrhea and Drooling in Corticobasal Syndrome
45%
see_also
📖
Simultanagnosia and Balint's Syndrome in Corticobasal S
45%
see_also
📖
SNCA A53T
45%
see_also
📖
TARDBP Mutations in Amyotrophic Lateral Sclerosis
45%
see_also
📖
Vocational Rehabilitation and Driving in Corticobasal Syndro
45%
see_also
📖
Voice and Speech in Corticobasal Syndrome
45%
see_also
📖
TREM2 Gene
45%
see_also
📖
Neuroimmune Response in 4R-Tauopathies: Cross-Disease Compar
45%
see_also
📖
ALS Biomarkers and Disease Monitoring
45%
see_also
📖
ALS Combination Therapy Matrix
45%
see_also
📖
ALS Mechanistic Pathway
45%
see_also
📖
VEGF and Angiogenesis Dysregulation in CBS/PSP
45%
see_also
📖
Pupillometry and Chromatic Pupillometry in Corticobasal Synd
45%
see_also
📖
FTDP-17 Clinical Phenotypes and Disease Progression
45%
see_also
📖
Gene-Mechanism-Therapy Causal Chains
45%
see_also
📖
Iron and Neuromelanin Accumulation in PSP
45%
see_also
📖
LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par
45%
see_also
📖
microglial-synaptic-pruning-dysregulation
45%
see_also
📖
MSA Clinical Features and Diagnosis
45%
see_also
📖
MSA Glial Pathology — Detailed Comparison with Parkinson
45%
see_also
📖
msa-pathophysiology-disease-mechanisms
45%
see_also
📖
Neuroimmune Interface Pathway
45%
see_also
📖
NLRP3 Inflammasome Inhibitors for Parkinson's Disease
45%
see_also
📖
NLRP3 Inhibitors in Parkinson's Disease: Research and C
45%
see_also
📖
Astrocytic Pathology in Progressive Supranuclear Palsy
45%
see_also
📖
Gait and Balance Disorders in Progressive Supranuclear Palsy
45%
see_also
📖
PSP Lysosomal Dysfunction and Autophagy Impairment
45%
see_also
📖
Pupillary and Visual Dysfunction in Progressive Supranuclear
45%
see_also
📖
PSP Tau Propagation and Spreading Mechanisms
45%
see_also
📖
PSP Weight Loss and Cachexia
45%
see_also
📖
Sleep Architecture Changes in CBS and PSP
45%
see_also
📖
Somatic Mutations and Brain Mosaicism
45%
see_also
📖
Speech and Language Deficits in Corticobasal Syndrome
45%
see_also
📖
TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain
45%
see_also
📖
TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th
45%
mentions
🔬
What are the mechanisms underlying astrocyte reactivity subt
40%
mentions
🔬
What are the mechanisms underlying digital biomarkers and ai
40%
mentions
🔬
What are the mechanisms underlying senolytic therapy for age
40%
mentions
🔬
What are the mechanisms underlying mechanistic role of apoe
40%
mentions
🔬
Investigate how lipid raft composition (cholesterol metaboli
40%
mentions
🔬
What are the mechanisms underlying sleep disruption as cause
40%
mentions
🔬
What are the mechanisms underlying epigenetic clocks and bio
40%
mentions
🔬
Analyze circuit-level changes in neurodegeneration using All
40%
mentions
🔬
Comprehensive analysis of immune cell subtypes in neurodegen
40%
mentions
🧫
Microglial TREM2 Agonist In Vivo Efficacy
40%
mentions
🧫
TREM2 Agonist Therapy for Parkinson's Disease — Experim
40%
mentions
🧫
TREM2 Function in Alzheimer's Disease — From Risk Varia
40%
mentions
🧪
Senescent Cell Mitochondrial DNA Release
40%
mentions
🧪
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
40%
mentions
🧪
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
40%
mentions
🧪
Synthetic Biology BBB Endothelial Cell Reprogramming
40%
mentions
🧪
Senescent Microglia Resolution via Maresins-Senolytics Combi
40%
mentions
🧪
Orexin-Microglia Modulation Therapy
40%
related
🧪
Temporal Decoupling via Circadian Clock Reset
40%
related
🧪
TREM2 Conformational Stabilizers for Synaptic Discrimination
40%
related
🧪
Netrin-1 Gradient Restoration
40%
related
🧪
Smartphone-Detected Motor Variability Correction
40%
related
🧪
Purinergic Signaling Polarization Control
40%
related
🧪
Mitochondrial-Lysosomal Contact Site Engineering
40%
related
🧪
Osmotic Gradient Restoration via Selective AQP1 Enhancement
40%
related
🧪
Circadian-Synchronized Proteostasis Enhancement
40%
related
🧪
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
40%
related
🧪
Selective HDAC3 Inhibition with Cognitive Enhancement
40%
related
🧪
HSP90-Tau Disaggregation Complex Enhancement
40%
related
🧪
Selective APOE4 Degradation via Proteolysis Targeting Chimer
40%
related
🧪
Ganglioside Rebalancing Therapy
40%
related
🧪
Mitochondrial SPM Synthesis Platform Engineering
40%
related
🧪
CX43 hemichannel engineering enables size-selective mitochon
40%
related
🧪
VCP-Mediated Autophagy Enhancement
40%
related
🧪
Arginine Methylation Enhancement Therapy
40%
related
🧪
Senescent Cell Mitochondrial DNA Release
40%
related
🧪
SASP-Mediated Cholinergic Synapse Disruption
40%
related
🧪
Mitochondrial RNA Granule Rescue Pathway
40%
related
🧪
Multi-Modal Stress Response Harmonization
40%
related
🧪
Complement C1q Mimetic Decoy Therapy
40%
related
🧪
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
40%
related
🧪
RAB27A-dependent extracellular vesicle engineering for mitoc
40%
related
🧪
CYP46A1 Overexpression Gene Therapy
40%
related
🧪
Enteric Nervous System Prion-Like Propagation Blockade
40%
related
🧪
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
40%
related
🧪
Retinal Vascular Microcirculation Rescue
40%
related
🧪
Metabolic Reprogramming via Microglial Glycolysis Inhibition
40%
related
🧪
Astroglial Gap Junction Coordination via Connexin-43 Phospho
40%
related
🧪
Metabolic Circuit Breaker via Lipid Droplet Modulation
40%
related
🧪
Senescent Microglia Resolution via Maresins-Senolytics Combi
40%
related
🧪
Noradrenergic-Tau Propagation Blockade
40%
related
🧪
Adenosine-Astrocyte Metabolic Reset
40%
related
🧪
AMPK hypersensitivity in astrocytes creates enhanced mitocho
40%
related
🧪
APOE4 Allosteric Rescue via Small Molecule Chaperones
40%
related
🧪
Palmitoylation-Targeted BACE1 Trafficking Disruptors
40%
related
🧪
Microglial Efferocytosis Enhancement via GPR32 Superagonists
40%
related
🧪
Biorhythmic Interference via Controlled Sleep Oscillations
40%
related
🧪
Quantum Coherence Disruption in Cellular Communication
40%
related
🧪
Nutrient-Sensing Epigenetic Circuit Reactivation
40%
related
🧪
LRP1-Dependent Tau Uptake Disruption
40%
related
🧪
Cryptic Exon Silencing Restoration
40%
related
🧪
SIRT6-NAD+ Axis Enhancement Therapy
40%
related
🧪
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
40%
related
🧪
Extracellular Vesicle Biogenesis Modulation
40%
related
🧪
Circadian Rhythm Entrainment of Reactive Astrocytes
40%
related
🧪
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
40%
related
🧪
SASP-Mediated Complement Cascade Amplification
40%
related
🧪
Complement C1q Subtype Switching
40%
related
🧪
Microglial Purinergic Reprogramming
40%
related
🧪
Heat Shock Protein 70 Disaggregase Amplification
40%
related
🧪
Autophagosome Maturation Checkpoint Control
40%
related
🧪
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
40%
related
🧪
Glymphatic System-Enhanced Antibody Clearance Reversal
40%
related
🧪
Prefrontal sensory gating circuit restoration via PV interne
40%
related
🧪
Chaperone-Mediated APOE4 Refolding Enhancement
40%
related
🧪
Sphingolipid Metabolism Reprogramming
40%
related
🧪
PARP1 Inhibition Therapy
40%
related
🧪
Low Complexity Domain Cross-Linking Inhibition
40%
related
🧪
Ocular Immune Privilege Extension
40%
related
🧪
Hypocretin-Neurogenesis Coupling Therapy
40%
related
🧪
Gut Barrier Permeability-α-Synuclein Axis Modulation
40%
related
🧪
GAP43-mediated tunneling nanotube stabilization enhances neu
40%
related
🧪
Extracellular Matrix Stiffness Modulation
40%
related
🧪
Synaptic Vesicle Tau Capture Inhibition
40%
related
🧪
Pericyte Contractility Reset via Selective PDGFR-β Agonism
40%
related
🧪
Microbial Metabolite-Mediated α-Synuclein Disaggregation
40%
related
🧪
Perforant Path Presynaptic Terminal Protection Strategy
40%
related
🧪
Optogenetic Microglial Deactivation via Engineered Inhibitor
40%
related
🧪
DNMT1-Targeting Antisense Oligonucleotide Reset
40%
related
🧪
Senescence-Induced Lipid Peroxidation Spreading
40%
related
🧪
Piezoelectric Nanochannel BBB Disruption
40%
related
🧪
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
40%
related
🧪
Lipid Droplet Dynamics as Phenotype Switches
40%
related
🧪
Circadian-Synchronized LRP1 Pathway Activation
40%
related
🧪
Glycine-Rich Domain Competitive Inhibition
40%
related
🧪
SASP-Driven Aquaporin-4 Dysregulation
40%
related
🧪
Axonal RNA Transport Reconstitution
40%
related
🧪
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
40%
related
🧪
Circadian-Gated Maresin Biosynthesis Amplification
40%
related
🧪
Synthetic Biology BBB Endothelial Cell Reprogramming
40%
related
🧪
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
40%
related
🧪
Orexin-Microglia Modulation Therapy
40%
related
🧪
KDM6A-Mediated H3K27me3 Rejuvenation
40%
related
🧪
Lysosomal Membrane Repair Enhancement
40%
related
🧪
Sleep Spindle-Synaptic Plasticity Enhancement
40%
related
🧪
Lysosomal Calcium Channel Modulation Therapy
40%
related
🧪
Astrocyte-Mediated Neuronal Epigenetic Rescue
40%
related
🧪
Blood-Brain Barrier SPM Shuttle System
40%
related
🧪
Mitochondrial Transfer Pathway Enhancement
40%
related
🧪
Stress Granule Phase Separation Modulators
40%
related
🧪
TFAM overexpression creates mitochondrial donor-recipient gr
40%
related
🧪
Interfacial Lipid Mimetics to Disrupt Domain Interaction
40%
related
🧪
Pharmacological Enhancement of APOE4 Glycosylation
40%
related
🧪
Membrane Cholesterol Gradient Modulators
40%
related
🧪
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
40%
related
🧪
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
40%
related
🧪
Flotillin-1 Stabilization Compounds
40%
related
🧪
Metabolic Switch Targeting for A1→A2 Repolarization
40%
related
🧪
Targeted APOE4-to-APOE3 Base Editing Therapy
40%
related
🧪
Temporal TET2-Mediated Hydroxymethylation Cycling
40%
related
🧪
HDAC3-Selective Inhibition for Clock Reset
40%
related
🧪
Magnetosonic-Triggered Transferrin Receptor Clustering
40%
related
🧪
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
40%
related
🧪
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
40%
related
🧪
Chromatin Accessibility Restoration via BRD4 Modulation
40%
related
🧪
Transcriptional Autophagy-Lysosome Coupling
40%
related
🧪
Digital Twin-Guided Metabolic Reprogramming
40%
related
🧪
TREM2-mediated microglial tau clearance enhancement
40%
related
🧪
Lysosomal Positioning Dynamics Modulation
40%
related
🧪
Lysosomal Enzyme Trafficking Correction
40%
related
🧪
Circadian Clock-Autophagy Synchronization
40%
related
🧪
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
40%
related
🧪
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
40%
related
🧪
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
40%
related
🧪
Senescence-Associated Myelin Lipid Remodeling
40%
related
🧪
Gamma entrainment therapy to restore hippocampal-cortical sy
40%
related
🧪
Glial Glycocalyx Remodeling Therapy
40%
related
🧪
R-Loop Resolution Enhancement Therapy
40%
related
🧪
Aquaporin-4 Polarization Rescue
40%
related
🧪
Senescence-Activated NAD+ Depletion Rescue
40%
related
🧪
Competitive APOE4 Domain Stabilization Peptides
40%
related
🧪
Epigenetic Memory Erasure via TET2 Activation
40%
related
🧪
Reelin-Mediated Cytoskeletal Stabilization Protocol
40%
related
🧪
HCN1-Mediated Resonance Frequency Stabilization Therapy
40%
related
🧪
TET2-Mediated Demethylation Rejuvenation Therapy
40%
related
🧪
Mechanosensitive Ion Channel Reprogramming
40%
related
🧪
Serine/Arginine-Rich Protein Kinase Modulation
40%
related
🧪
Selective Acid Sphingomyelinase Modulation Therapy
40%
related
🧪
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
40%
related
🧪
Vocal Cord Neuroplasticity Stimulation
40%
related
🧪
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
40%
related
🧪
Synthetic Biology Rewiring via Orthogonal Receptors
40%
related
🧪
Ephrin-B2/EphB4 Axis Manipulation
40%
related
🧪
Microbial Inflammasome Priming Prevention
40%
related
🧪
Phase-Separated Organelle Targeting
40%
related
🧪
Nucleolar Stress Response Normalization
40%
related
🧪
Vagal Afferent Microbial Signal Modulation
40%
related
🧪
Cross-Seeding Prevention Strategy
40%
related
🧪
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
40%
related
🧪
Purinergic P2Y12 Inverse Agonist Therapy
40%
related
🧪
Microbiome-Derived Tryptophan Metabolite Neuroprotection
40%
related
🧪
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
40%
related
🧪
Near-infrared light therapy stimulates COX4-dependent mitoch
40%
related
🧪
FOXO3-Longevity Pathway Epigenetic Reprogramming
40%
related
🧪
Trans-Synaptic Adhesion Molecule Modulation
40%
related
🧪
Sphingomyelin Synthase Activators for Raft Remodeling
40%
related
🧪
RNA Granule Nucleation Site Modulation
40%
related
🧪
Mitochondrial RNA Granule Rescue Pathway
40%
related
🧪
Axonal RNA Transport Reconstitution
40%
related
🧪
RNA Granule Nucleation Site Modulation
40%
mentions
🔬
What are the most promising therapeutic strategies for targe
32%
mentions
🔬
Can gut-brain axis modulation prevent or slow Alzheimer'
32%
mentions
🔬
How to break the GBA-alpha-synuclein bidirectional loop for
32%
mentions
🔬
Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea
32%
mentions
🔬
The disease-associated microglia (DAM) phenotype involves TR
32%
mentions
🔬
What are the mechanisms underlying what are the mechanisms b
32%
mentions
🔬
What are the mechanisms underlying what are the mechanisms b
32%
mentions
🔬
The disease-associated microglia (DAM) phenotype involves TR
32%
mentions
🔬
Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph
32%
mentions
🔬
What are the mechanisms underlying microglia-astrocyte cross
32%
mentions
🔬
What are the mechanisms underlying synaptic pruning by micro
32%
mentions
🔬
Analyze the spectrum of microglial activation states (DAM, h
32%
mentions
🔬
Senolytics targeting p16/p21+ senescent astrocytes and micro
32%
mentions
🔬
Synaptic pruning by microglia in early AD
32%
mentions
🔬
What cell types are most vulnerable in Alzheimers Disease ba
32%
mentions
🔬
What cell types are most vulnerable in Alzheimer's Dise
32%
related
🔬
What are the mechanisms underlying selective vulnerability o
24%